How often should guideline-directed medical therapy doses be titrated in stable patients?

• A. Never adjust after starting
• B. Every day
• C. Every 2-4 weeks until target doses and tolerability are reached
• D. Once a year

Answer: (C)

Titrate GDMT doses at regular intervals to reach the doses proven to improve outcomes while ensuring safety. In stable heart failure patients, the typical plan is to increase the dose every 2–4 weeks. This cadence gives enough time for hemodynamic adaptation and for you to monitor important safety signals—blood pressure, heart rate, kidney function, and electrolytes—before raising the dose again. If the patient tolerates the dose without adverse effects, you continue uptitration toward the target doses; if intolerance or labs raise concerns, you adjust accordingly or delay further increases.

Choosing not to adjust after starting misses the opportunity to reach the proven-benefit doses, while increasing every day is impractical and risks instability, and waiting a full year would delay substantial improvement. The goal is steady, safe progression toward optimal dosing based on tolerability and lab monitoring.